Cogent Biosciences, Inc. stock is down 0% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.
Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
---|---|---|---|---|---|
20 Nov 18:52 | 17 May, 2024 | 5.00 | 0 |
Cogent Biosciences, Inc. focuses on developing precision therapies for genetically defined diseases. Lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis.